BACKGROUND: The aim of this study was to investigate the clinical characteristics, exercise training response, β-blocker selectivity, and outcomes in patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD). METHODS: We performed an analysis of HF-ACTION, which randomized 2,331 patients with HF having an ejection fraction of ≤35% to usual care with or withoutaerobic exercise training. We examined clinical characteristics and outcomes (mortality/hospitalization, mortality, cardiovascular [CV] mortality/CV hospitalization, and CV mortality/HF hospitalization) by physician-reported COPD status using adjusted Cox models and explored an interaction with exercise training. The interaction between β-blocker cardioselectivity and outcomes was investigated. RESULTS: Of patients with COPD status documented (n = 2311), 11% (n = 249) had COPD. Patients with COPD were older, had more comorbidities, and had lower use of β-blockers compared with those without COPD. At baseline, patients with COPD had lower peak oxygen consumption and higher V(E)/V(CO)(2) slope. During a median follow-up of 2.5 years, COPD was associated with increased mortality/hospitalization, mortality, and CV mortality/HF hospitalization. After multivariable adjustment, the risk of CV mortality/HF hospitalization remained increased (hazard ratio [HR] 1.46, 95% CI 1.14-1.87), whereas mortality/hospitalization (HR 1.15, 95% CI 0.96-1.37) and mortality (HR 1.33, 95% CI 0.99-1.76) were not significantly increased. There was no interaction between COPD and exercise training on outcomes or between COPD and β-blocker selectivity on mortality/hospitalization (all P > .1). CONCLUSIONS:Chronic obstructive pulmonary disease in patients with HF was associated with older age, more comorbidities, reduced exercise capacity, and increased CV mortality/HF hospitalization, but not a differential response to exercise training. β-Blocker selectivity was not associated with differences in outcome for patients with vs without COPD.
RCT Entities:
BACKGROUND: The aim of this study was to investigate the clinical characteristics, exercise training response, β-blocker selectivity, and outcomes in patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD). METHODS: We performed an analysis of HF-ACTION, which randomized 2,331 patients with HF having an ejection fraction of ≤35% to usual care with or without aerobic exercise training. We examined clinical characteristics and outcomes (mortality/hospitalization, mortality, cardiovascular [CV] mortality/CV hospitalization, and CV mortality/HF hospitalization) by physician-reported COPD status using adjusted Cox models and explored an interaction with exercise training. The interaction between β-blocker cardioselectivity and outcomes was investigated. RESULTS: Of patients with COPD status documented (n = 2311), 11% (n = 249) had COPD. Patients with COPD were older, had more comorbidities, and had lower use of β-blockers compared with those without COPD. At baseline, patients with COPD had lower peak oxygen consumption and higher V(E)/V(CO)(2) slope. During a median follow-up of 2.5 years, COPD was associated with increased mortality/hospitalization, mortality, and CV mortality/HF hospitalization. After multivariable adjustment, the risk of CV mortality/HF hospitalization remained increased (hazard ratio [HR] 1.46, 95% CI 1.14-1.87), whereas mortality/hospitalization (HR 1.15, 95% CI 0.96-1.37) and mortality (HR 1.33, 95% CI 0.99-1.76) were not significantly increased. There was no interaction between COPD and exercise training on outcomes or between COPD and β-blocker selectivity on mortality/hospitalization (all P > .1). CONCLUSIONS:Chronic obstructive pulmonary disease in patients with HF was associated with older age, more comorbidities, reduced exercise capacity, and increased CV mortality/HF hospitalization, but not a differential response to exercise training. β-Blocker selectivity was not associated with differences in outcome for patients with vs without COPD.
Authors: Jonathan Myers; Ross Arena; Frederick Dewey; Daniel Bensimhon; Joshua Abella; Leon Hsu; Paul Chase; Marco Guazzi; Mary Ann Peberdy Journal: Am Heart J Date: 2008-09-16 Impact factor: 4.749
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: Andrew Jabbour; Peter S Macdonald; Anne M Keogh; Eugene Kotlyar; Soren Mellemkjaer; Cathie F Coleman; Maros Elsik; Henry Krum; Christopher S Hayward Journal: J Am Coll Cardiol Date: 2010-04-27 Impact factor: 24.094
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Cynthia D Brown; Joshua O Benditt; Frank C Sciurba; Shing M Lee; Gerard J Criner; Zab Mosenifar; David M Shade; William A Slivka; Robert A Wise Journal: COPD Date: 2008-04 Impact factor: 2.409
Authors: Christopher M O'Connor; William T Abraham; Nancy M Albert; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Clyde W Yancy; James B Young; Gregg C Fonarow Journal: Am Heart J Date: 2008-10 Impact factor: 4.749
Authors: Nathaniel Mark Hawkins; Mark C Petrie; Pardeep S Jhund; George W Chalmers; Francis G Dunn; John J V McMurray Journal: Eur J Heart Fail Date: 2009-02 Impact factor: 15.534
Authors: Jacob P Kelly; Allison Dunning; Phillip J Schulte; Mona Fiuzat; Eric S Leifer; Jerome L Fleg; Lawton S Cooper; Steven J Keteyian; Dalane W Kitzman; Ileana L Pina; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz Journal: JACC Heart Fail Date: 2016-07-06 Impact factor: 12.035
Authors: Robert J Mentz; Michael A Babyak; Vera Bittner; Jerome L Fleg; Steven J Keteyian; Ann M Swank; Ileana L Piña; William E Kraus; David J Whellan; Christopher M O'Connor; James A Blumenthal Journal: Circ Heart Fail Date: 2015-04-21 Impact factor: 8.790
Authors: Mary O Whipple; Erica N Schorr; Kristine M C Talley; Ruth Lindquist; Ulf G Bronas; Diane Treat-Jacobson Journal: J Aging Phys Act Date: 2018-06-20 Impact factor: 1.961
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: Robert J Mentz; Vera Bittner; Phillip J Schulte; Jerome L Fleg; Ileana L Piña; Steven J Keteyian; Gordon Moe; Anil Nigam; Ann M Swank; Anekwe E Onwuanyi; Meredith Fitz-Gerald; Andrew Kao; Stephen J Ellis; William E Kraus; David J Whellan; Christopher M O'Connor Journal: Am Heart J Date: 2013-07-12 Impact factor: 4.749
Authors: Randall E Keyser; Joshua G Woolstenhulme; Lisa M K Chin; Steven D Nathan; Nargues A Weir; Gerilynn Connors; Bart Drinkard; James Lamberti; Leighton Chan Journal: J Cardiopulm Rehabil Prev Date: 2015 Jan-Feb Impact factor: 2.081
Authors: Lauren B Cooper; Robert J Mentz; Jie-Lena Sun; Phillip J Schulte; Jerome L Fleg; Lawton S Cooper; Ileana L Piña; Eric S Leifer; William E Kraus; David J Whellan; Steven J Keteyian; Christopher M O'Connor Journal: Circ Heart Fail Date: 2015-11 Impact factor: 8.790